Figure 1.

Flies have extraordinary utility for use in drug screening protocols to advance discoveries for human health. Flies have been used extensively in drug discovery, in large part due to their ease of use and relevance to human disease models (Fernández-Hernández et al., 2016; Su, 2019). Small molecules have been identified in screens with relevance to several human disease conditions including cancer (Willoughby et al., 2013; Yadav et al., 2016; Bangi, 2019; Al Outa et al., 2020), pain and inflammatory disease (Grimes et al., 2020), sleep and circadian rhythm (Nall and Sehgal, 2013; Wang et al., 2020), neurodegenerative (ND) disorders including Alzheimer's disease (Hannan et al., 2016; Elovsson et al., 2021), Parkinson's disease (Sanz et al., 2021), Huntington's disease (Sarkar et al., 2007; Schulte et al., 2011), Lysosomal storage disorders (Rigon et al., 2021), Alexander disease (Wang et al., 2016), Friedreich's disease (Seguin et al., 2015), Fragile X syndrome (Chang et al., 2008), Ataxia-telangiectasia (Rimkus and Wassarman, 2018), obesity (Gasque et al., 2013), atrial fibrillation (van Marion et al., 2019), and in human hazard identification (testing potential genotoxins such as food, dietary supplements, cosmetics, drugs, pesticides, herbicides, and nanoparticles) (Barik and Mishra, 2019; Pitchakarn et al., 2021). Created with BioRender.com.